Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry
  1. WHRI
  2. People
  3. Academic staff
  4. Items

Professor Anthony Mathur

Anthony

Centre for Cardiovascular Medicine and Devices - Centre Lead

Centre: Cardiovascular Medicine and Devices

Email: a.mathur@qmul.ac.uk
Telephone: +44(0) 20 3765 8740

Profile

I divide my time equally between clinical work and translational medicine and research. My research focuses on examining the role of biologics (stem cells, gene therapy, cellular bioenergetics, megakaryocyte biology) in the treatment of cardiovascular disease. As the Clinical Director for Interventional Cardiology at Barts Health, my clinical work is directed towards the management of patients who have failed conventional therapy for heart failure and angina. Furthermore, I Chair the ESC Task Force on stem cells in cardiovascular disease and, previously, I Chaired the British Cardiac Stem Cells Collaborative set up by Prof. John Martin. I also lead the Compassionate Stem Cell Treatment Unit for patients with cardiac disease at Barts Heart Centre.

Within the Centre for Cardiovascular Medicine and Devices, I lead the Cardiovascular Devices Hub (CVD HUB). The CVDHub supports collaborations between academic, clinical, engineering and industrial innovators to develop clinically and commercially viable cardiovascular devices. This novel, cross-speciality unit helps small to medium enterprises (SMEs) over the hurdles involved in taking innovations to human trials. Within device innovation, I focus on first-in-man trials, digital technologies (e.g Avatars) and artificial intelligence.

Research

I lead a collaborative group with several investigators (including Prof. John Martin (UCL), Prof. Amrita Ahluwalia (Queen Mary), Prof. Andreas Baumbach (Queen Mary) and Prof. Alexandra Lansky (Yale) seeking to address the role of biologics in the treatment of cardiovascular disease; translating basic research into therapeutic approaches in man. My interventional cardiology research aims to develop new treatments for patients that fall outside the remit of current recognised therapies. I have designed a series of trials addressing the use of stem cells in the treatment of cardiovascular disease, and am currently the CI for one of the first Phase III clinical trials of cell therapy in acute myocardial infarction. I am also interested in the use of advanced cardiac imaging, and established the first Cardiac CMR service at Barts Health.

Publications

  • Serruys PW, Tsai T-Y, Wykrzykowska JJ et al. (2026). Angiography-derived fractional flow reserve- vs usual care-guided percutaneous coronary intervention: interim analysis of the PIONEER IV trial. nameOfConference


    QMRO: qmroHref
  • Yap NAL, Bourantas CV, Losdat S et al. (2026). Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation ― Post Hoc Analysis of the PACMAN-AMI Study ―. nameOfConference


    QMRO: qmroHref
  • Yap NAL, He X, Tanboga IH et al. (2026). Effect of computed tomography reconstruction algorithms on coronary atheroma composition against multimodality near-infrared spectroscopy intravascular ultrasound. Light in Cardiology 2026


    QMRO: qmroHref
  • Rauseo E, Bevis L, Chen X et al. (2026). Understanding the mechanisms of TAVI durability through computational modelling: a multidisciplinary review. nameOfConference


  • Ramsay T, Jones J, Coldea B et al. (2026). DEBS-035 | A dilemma solved with a DEB – hybrid revascularisation with a Drug Eluting Balloon and Drug Eluting Stent for avoidance of Coronary Artery Bypass Surgery in the setting of unclear left ventricular viability. nameOfConference


    QMRO: qmroHref
  • Rathod KS, Kelham M, Choudry F et al. (2026). DEBS-057 | STEMI in a Post-CABG Patient - should we DCB or DES a Saphenous Vein Graft?. nameOfConference


    QMRO: qmroHref
  • Bajaj R, Huang X, Alves-Kotzev N et al. (2026). Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head-to-head comparison against histology. nameOfConference


  • Kelham M, Beirne A-M, Learoyd AE et al. (2026). Computed tomography coronary angiography to facilitate clinical decision-making and selective invasive angiography in patients with prior bypass grafting presenting with acute coronary syndromes. nameOfConference


  • He X, Bransby KM, Ulutas AE et al. (2026). A novel framework for fully automated co-registration of intravascular ultrasound and optical coherence tomography imaging data. nameOfConference


  • Jones J, Morgan H, Rathod K et al. (2026). The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus. nameOfConference


View profile publication page

Sponsors

 

News

Disclosures

I disclose the following relevant interests from the past 3 years:

  • Board Member - IoNa Therapeutics: Company number 15704565
  • Board Member - Heart Cells Company: Company number 10282577
  • Inventor on US Patent No. 11,191,877 - 'Magnetised Coronary Stent'
  • Inventor on Japanese Patent No. 6650930 - 'Stem Cell Delivery Method'
  • Inventor on UK Patent Application No.2508620: Method for managing blood pressure
  • Inventor on UK Patent Application No. 2411474.6: “Medical Support Method” describing a pipeline for TAVR digital twin simulation.
  • Inventor on International Patent application PCT/GB2025/051004 - Method for selection of cells with reparative potential
  • 2004-Present: Trustee of the Heart Cells Foundation Charity
  • 2025: Honoraria  - Advisory Board for Abbott

 

Back to top